The mechanism of tetrahydroaminoacridine‐evoked release of endogenous 5‐hydroxytryptamine and dopamine from rat brain tissue prisms
Open Access
- 1 December 1989
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 98 (4), 1127-1136
- https://doi.org/10.1111/j.1476-5381.1989.tb12656.x
Abstract
1 Tetrahydroaminoacridine (THA) is an acetylcholinesterase (AChE) inhibitor which may have a greater therapeutic effect in Alzheimer-type dementia (ATD) than other cholinergic agents. This suggests possible non-cholinergic properties. We have therefore studied the effects of THA on the release of endogenous 5-hydroxytryptamine (5-HT) from rat cortical prisms and dopamine from striatal prisms. 2 In the presence of K+ (1 mm), THA stimulated release of both 5-HT and dopamine. THA (100 μm)-evoked monoamine release was comparable, but not additive with the release produced by K+ (35 mm). The effect was not maximal at 1 mM THA. THA-evoked release of 5-HT was independent of the presence of Ca2+ in the external medium. 3 Drugs acting on the cholinergic system, nicotine, mecamylamine, atropine, oxotremorine, physostigmine and neostigmine (all 10 μm) had no effect on 5-HT and dopamine release. 4-Aminopyridine (4-AP), a potent acetylcholine-releasing agent, had no effect on 5-HT release and was approximately 100 fold less active than THA on dopamine release. 4 Both THA and reserpine enhanced the release of 5-HT in the presence of the monoamine oxidase inhibitor, pargyline. Reserpine- but not THA-evoked release was abolished in the absence of pargyline. Reserpine (5 mg kg−1, i.p.) markedly depleted brain monoamine concentrations 3 h after injection, while THA (15 mg kg−1, i.p.) had no effect. 5 Chloroamphetamine and fenfluramine both released 5-HT in a Ca2+-independent manner and with a similar potency to THA, while (+)-amphetamine released dopamine with a similar potency to THA. The effects of the amphetamines were not maximal at 1 mM. However, unlike THA, chloroamphetamine-evoked release of 5-HT was additive with release evoked by K+ (35 mm). 6 Clomipramine (IC50 = 0.036 μm), imipramine (IC50 = 0.20 μm) and THA (IC50 = 19.9 μm) all inhibited the uptake of [3H]-5-HT into a P2 membrane preparation. However, none of these compounds inhibited [3H]-5-HT uptake into tissue prisms during the release experiments in which the reuptake inhibitor fluoxetine (5 μm) was present. 7 We conclude that THA does not release endogenous 5-HT through a cholinergic, reserpine- or amphetamine-like mechanism or through inhibition of reuptake. The possibility exists that the release may occur via blockade of 4-AP-insensitive K+ channels.This publication has 34 references indexed in Scilit:
- Effects of tetrahydroaminoacridine on M1 and M2 muscarine receptorsNeuroscience Letters, 1988
- Stereoselective Nicotine‐Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive StimulationJournal of Neurochemistry, 1988
- Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's diseaseLife Sciences, 1988
- Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors?Journal of Neural Transmission, 1987
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986
- Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptorsGeneral Pharmacology: The Vascular System, 1983
- Enhancement of [3H]dopamine release and its [3H]metabolites in rat striatum by nicotinic drugsBrain Research, 1982
- Regulation of dopamine release by presynaptic nicotinic receptors in rat striatal slices: Effect of nicotine in a low concentrationLife Sciences, 1979
- The effect of 4-aminopyridine on acetylcholine releaseJournal of Neural Transmission, 1977
- THE PHARMACOLOGY OF SOME NEW ANTI‐CHOLINESTERASESImmunology & Cell Biology, 1953